Accelerating Autologous CAR T Cell Expansion With The Automated, End To End Sefia™ Cell Therapy Platform

By Yanling Liu, Anna Maystrenko, Srinidhi Deshpande, Genna Luciani, Dana Arab, Cindy Farino Reyes, Mack Ryan, Nick McKenzie, Craig Mizzoni, Federico Franchi, and Azher Razvi

Autologous CAR T therapies have redefined outcomes in hematologic cancers, yet sustained responses in solid tumors and certain lymphomas remain elusive. Achieving durable efficacy often demands repeat dosing, intensifying pressure on manufacturing to deliver high-expansion T cells without driving exhaustion while still meeting tight timelines for patient treatment. Complex, multi-step production workflows further increase operational burden, requiring skilled operators and rigorous documentation to satisfy regulatory expectations. A modular, semi-automated approach offers a path forward by simplifying execution and strengthening process control. Integrating closed manufacturing with digital batch records can reduce variability, streamline traceability, and accelerate throughput.

Explore how advancing manufacturing strategies can help unlock broader access and clinical impact.